BioAro Inc. has made a significant advancement in artificial intelligence with the introduction of the world”s first large language model (LLM) based on unified multi-omics data. This innovative technology, named “The BioIntelligence,” was announced on October 27, 2025, and will be featured at the Global Health Exhibition in Riyadh. This model aims to transform our understanding of the intricate interactions among genes, proteins, and metabolites, enabling a comprehensive view of human biology.
The announcement highlights a persistent challenge in contemporary medicine: the fragmentation of biological data. Researchers often face an overload of isolated genomic, proteomic, and metabolomic information without a clear method to synthesize these insights into a coherent narrative. This disconnection has hindered progress in understanding complex diseases like cancer and diabetes, ultimately delaying the development of personalized treatments. With the launch of PanOmiQ, BioAro seeks to bridge these gaps by providing a clear understanding of health and disease dynamics through its multi-omics LLM.
“We have moved from counting words to understanding poetry—the poetry written in the language of our own cells,” stated Dr. Anmol Kapoor, Founder and CEO of BioAro. He emphasized that this new technology transforms disparate data into a meaningful dialogue between patients and their biology, paving the way for proactive healthcare solutions.
In addressing the need for robust data security, BioAro has designed PanOmiQ for on-premises deployment, ensuring that sensitive genetic information is safeguarded within healthcare settings. The platform utilizes a combination of FPGA acceleration and GPU computing, allowing it to function as an independent intelligence unit within hospitals and laboratories.
The BioIntelligence ecosystem is further enhanced by the introduction of the Axion series, a proprietary range of intelligent hardware systems. This series is tailored to deliver sovereign AI computation for healthcare and research, enabling seamless deployment across various operational environments. The Axion series includes different tiers—Core, Ultra, and Supreme—catering to diverse processing and operational needs.
Commenting on the significance of this technology for the UAE and the broader Gulf region, Bader Al-Marzooqi, a prominent Emirati health-tech investor, remarked, “BioAro isn”t just importing technology; they are delivering a sovereign capability that aligns with our national vision for a secure, innovative, and proactive healthcare future.” This solution empowers healthcare providers while ensuring the protection of citizens” data.
At the Global Health Exhibition in Riyadh, BioAro plans to showcase the capabilities of its ecosystem, including live demonstrations of multi-omics analysis and interactive sessions with Genelio. Dr. Kapoor expressed that this initiative is more than just a product launch; it represents a movement towards intelligent, proactive healthcare.
BioAro Inc. is a Canada-based biotechnology and software company dedicated to advancing intelligent and sovereign health solutions. Their mission is to integrate biology with data science through The BioIntelligence, transforming complex molecular information into actionable health insights.
